Drug intelligence / Profile preview

devazepide

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

**Devazepide (MK-329)** is a potent and selective cholecystokinin (CCK) receptor antagonist, specifically antagonizing CCK-A (also known as CCK1) receptors. In preclinical studies, it was shown to modulate opioid-mediated analgesia through dose-dependent effects on CCK-A and CCK-B receptors. Devazepide exhibits no intrinsic analgesic effects but can potentiate or inhibit morphine- and opioid-mediated analgesia depending on context—suggesting differential receptor selectivity[1]. It is primarily developed as a research compound for exploring the physiological and pharmacological roles of CCK receptors[1][5].

Brand names: MK-329MK329MK 329
Other names: DevazepideDevazepidumDevazepida

Targets

CCK2R (Cholecystokinin 2 Receptor)CCKAR (Cholecystokinin A receptor)

Beyond the preview

Go deeper on devazepide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on devazepide.

Explore the full profile